<DOC>
	<DOCNO>NCT03096496</DOCNO>
	<brief_summary>This prospective international observational study run GIMEMA . All data centrally collect analyzed GIMEMA Data Center Rome ( Italy ) . Patients report outcomes collect use internationally validate questionnaire .</brief_summary>
	<brief_title>Long-term QoL Acute Promyelocytic Leukemia Treated With ATO Standard Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>APL survivor enrol GIMEMA APL0406 clinical trial first molecular CR third consolidation treatment Written inform consent . APL patient previously enrol GIMEMA APL0406 trial reach lose followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Quality life</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>ATO</keyword>
</DOC>